ArticleFrontiers in public health2025
Dabie bandavirus identified from patients with severe fever with thrombocytopenia syndrome in northwestern of Hubei Province, China, 2024.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe fever with thrombocytopenia syndrome (SFTS), caused by Dabie bandavirus (DBV), is a zoonotic disease characterized by substantial mortality. Hubei Province is an epidemic region with a high incidence rate of SFTS. The clinical manifestations and case fatality rates (CFRs) of SFTS correlate with specific geographic regions and genotypes of DBV. Methods: From January to December 2024, serum samples were obtained from 69 patients with suspected DBV infection in northwestern Hubei Province, China. The presence of DBV RNA was used as the diagnostic criterion for SFTS. Demographic characteristics, clinical manifestations, and laboratory findings of confirmed SFTS patients were systematically collected. Phylogenetic analyses of the DBV L, M, and S gene segments were performed using the maximum likelihood method to elucidate the genetic diversity of the viral isolates. Results: A total of 19 patients with confirmed SFTS were identified in northwestern Hubei Province in 2024, with a CFR of 31.6% (6/19). Clinical analyses indicated that bleeding, disturbance of consciousness, prolonged activated partial thromboplastin time (APTT), elevated blood urea nitrogen (BUN), and high viral load (≥10 Discussion: This study delineates the genomic diversity and genotype distribution of circulating DBV strains, providing insights into viral etiology in northwestern Hubei. Furthermore, specific clinical/laboratory markers may signal adverse outcomes, emphasizing the imperative for symptom recognition and dynamic monitoring of critical laboratory parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.